Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany

Annals of Internal Medicine

Volumn 128, Issue 5, 1998, Pages 337-345

  Niederau, Claus ^a   Niederau, Christoph M ^a   Lange, Stefan ^a,b   Littauer, Andrea ^a   Abdel Jalil, Nabil ^a   Maurer, Michael ^a,c   Häussinger, Dieter ^a   Strohmeyer, Georg ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Betriebsarztzentrum M   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON; TRANSFERRIN;

ADULT; ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; GERMANY; HEMOCHROMATOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IRON DEFICIENCY; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

EID: 0032032503     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-128-5-199803010-00001     Document Type: Article

References (30)

1. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med. 1993;328:1616-20.
2. Niederau C, Strohmeyer G, Stremmel W. Epidemiology, clinical spectrum and prognosis of hemochromatosis. Adv Exp Med Biol. 1994;356:293-302.
3. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med. 1988;318:1355-62.
4. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and noncirrhotic patients with primary haemochromatosis. N Engl J Med. 1985;313:1256-62.
5. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 1992;15:655-9.
6. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 1991;101:368-72.
7. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107-19.
8. Summers KM, Halliday JW, Powell LW. Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index. Hepatology. 1990;12:20-5.
9. Kent G, Popper H. Liver biopsy in diagnosis of hemochromatosis. Am J Med. 1968;44:837-41.
10. Loreal O, Deugnier Y, Moirand R, Lauvin L, Guyader D, Jouanolle H, et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol. 1992;16: 122-7.
11. Deugnier YM, Guyader D, Crantock L, Lopez JM, Turlin B, Yaouanq J, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology. 1993;104:228-34.
12. Valberg LS, Serbie J, Ludwig J, Pelletier O. Serum ferritin and the iron status of Canadians. Can Med Assoc J. 1976;114:417-21.
13. Milman N, Sondergaard M. Iron stores in male blood donors evaluated by serum ferritin. Transfusion. 1984;24:464-8.
14. Kushner JP. Hypochronic anemia. In: Wyngaarden JB, Smith LH Jr, Bennett JC, eds. Cecil Textbook of Medicine. 18th ed. Philadelphia: WB Saunders; 1992:839-48.
15. Summary of a report on assessment of the iron nutritional status of the United States population. Expert Scientific Working Group. Am J Clin Nutr. 1985;42:1318-30.
16. Nelson M, White J, Rhodes C. Haemoglobin, ferritin, and iron intakes in British children aged 12-14 years: a preliminary investigation. Br J Nutr. 1993; 70:147-55.
17. Oski FA. Iron deficiency in infancy and childhood. N Engl J Med. 1993;329: 190-3.
18. Pi DW, Krikler SH, Sparling TG, Carter CJ, Wadsworth LD. Reappraisal of optimal hemoglobin standards for female blood donors in Canada. Transfusion. 1994;34:7-10
19. Jonsson JJ, Johannesson GM, Sigfusson N, Magnusson B, Thjodleifsson B, Magnusson S, et al. Prevalence of iron deficiency and iron overload in the adult Icelandic population. J Clin Epidemiol. 1991;44:1289-97.
20. Cook JD, Skikne BS, Lynch SR, Reusser ME. Estimates of iron sufficiency in the US population. Blood. 1986;68:726-31.
21. Balan V, Baldus W, Fairbanks V, Michels V, Burritt M, Klee G. Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients. Gastroenterology. 1994;107:453-9.
22. Weinstein MC, Stason WB. Cost-effectiveness of interventions to prevent or treat coronary heart disease. Annu Rev Public Health. 1985;6:41-63.
23. Welch HG, Larson EB. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med. 1989;321:807-12.
24. Buffone GJ, Beck JR. Cost-effectiveness analysis for evaluation of screening programs: hereditary hemochromatosis. Clin Chem. 1994;40:1631-6.
25. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994; 154:769-76.
26. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology. 1995;109:177-88.
27. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med. 1996;335:1799-805.
28. Adams PC, Kertesz AE, Valberg LS. Screening for hemochromatosis in children of homozygotes: prevalence and cost-effectiveness. Hepatology. 1995;22:1720-7.
29. Gordeuk V, Mukiibi J, Hasstedt SJ, Samowitz W, Edwards CQ, West G, et al. Iron overload in Africa. Interaction between a gene and dietary iron content. N Engl J Med. 1992;326:95-100.
30. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34: 275-8.